SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome.


Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 25 8 2020
medline: 28 4 2021
entrez: 25 8 2020
Statut: ppublish

Résumé

T-cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy driven by abnormal activity of transcription factors. Here we report an aberrant expression of the developmental transcription factor

Identifiants

pubmed: 32835548
doi: 10.1080/10428194.2020.1804560
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
Homeodomain Proteins 0
Proto-Oncogene Proteins 0
SIX6 protein, human 0
T-Cell Acute Lymphocytic Leukemia Protein 1 0
Trans-Activators 0
TAL1 protein, human 135471-20-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3089-3100

Auteurs

Saara Laukkanen (S)

Faculty of Medicine and Health Technology, Tampere Center for Child Health Research, Tampere University, Tampere, Finland.

Laura Oksa (L)

Faculty of Medicine and Health Technology, Tampere Center for Child Health Research, Tampere University, Tampere, Finland.

Atte Nikkilä (A)

Faculty of Medicine and Health Technology, Tampere Center for Child Health Research, Tampere University, Tampere, Finland.

Mari Lahnalampi (M)

The Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.

Mataleena Parikka (M)

Faculty of Medicine and Health Technology, BioMediTech, Tampere University, Tampere, Finland.
Oral and Maxillofacial Unit, Tampere University Hospital, Tampere, Finland.

Masafumi Seki (M)

Department of Cell and Molecular Biology, Karolinska Institutet, Solna, Sweden.

Junko Takita (J)

Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Sofie Degerman (S)

Department of Medical Biosciences and Department of Clinical Microbiology, Umeå University, Umeå, Sweden.

Charles E de Bock (CE)

Children's Cancer Institute, Lowy Cancer Research Centre, Sydney, Australia.
School of Women's and Children's Health, University of New South Wales Sydney, Sydney, Australia.

Merja Heinäniemi (M)

The Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.

Olli Lohi (O)

Faculty of Medicine and Health Technology, Tampere Center for Child Health Research, Tampere University, Tampere, Finland.
Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH